



Review article

An overview of albumin and alpha-1-acid glycoprotein main characteristics: highlighting the roles of amino acids in binding kinetics and molecular interactions



Michel Bteich *

Department of Environmental and Occupational Health, School of Public Health, Université de Montréal, Montréal, Québec, Canada

ARTICLE INFO

Keywords:

Plasma protein binding
Protein-ligand complex
Albumin
Alpha-1-acid glycoprotein
Molecular interactions

ABSTRACT

Although Albumin (ALB) and alpha-1-acid glycoprotein (AGP) have distinctive structural and functional characteristics, they both play a key role in binding a large variety of endogenous and exogenous ligands.

An extensive binding to these plasma proteins could have a potential impact on drugs disposition (e.g. bioavailability, distribution and clearance), on their innocuity and their efficacy. This review summarizes the common knowledge about the structural and molecular characteristics of both ALB and AGP in humans, and about the most involved amino acids in their high-affinity binding pockets. However, the variability in residues found in binding pockets, for the same species, allows each plasma protein to interact differently with the ligands. The protein-ligand interaction influences differently the disposition of drugs that bind to either of these plasma proteins.

The content of this review is useful for the design of new drug entities with high-binding characteristics, in qualitative and quantitative modelling (e.g. *in vitro-in vivo* extrapolations, 3D molecular docking, interspecies extrapolations), and for other interdisciplinary research.

1. Introduction

In the human body, there are many plasma proteins that allow the binding of xenobiotics (drugs and/or contaminants) such as albumin (ALB), alpha-1-acid glycoprotein (AGP), lipoproteins (HDL, LDL, VLDL, and chylomicrons), fibrinogen, C-reactive protein, transferrin, α , β , γ -globulins, etc (Bowman, 1993; Kerns and Di, 2008; Putnam, 1984). ALB and AGP are the most important for two reasons: first, their main role is carriers and storage depot of the majority of exogenous and endogenous substances into the bloodstream (Lehman-McKeeman, 2013); second, ALB and AGP may be good biomarkers for inflammation and liver disease. They are also potential biomarkers for all-cause mortality, along with citrate and VLDL particle size (Fischer et al., 2014). Although both ALB and AGP have a key role in clinical pharmacokinetics (PK) and pharmacodynamics (PD) research, these plasma proteins have never been presented by contrasting their main characteristics from top to bottom. Therefore, the main objective of this review is to give an overview of the common knowledge about ALB and AGP in humans by contrasting their structural and functional characteristics. The composition in amino acids is also addressed for main sites of both plasma

proteins, in an effort to better understand the differences in the molecular interactions occurring between each plasma protein and its ligands.

2. Common knowledge about albumin and alpha-1-acid glycoprotein

2.1. Albumin

ALB is a single chain, non-glycosylated protein, primarily synthesized in the liver (Miller, 1951; Peters and Anfinson, 1950) and rapidly secreted in vesicles (13.3 g per day) to the extracellular space (Fries et al., 1984; Peters Jr., 1996). In humans, a mature ALB has 585 amino acids (AA) (Meloun et al., 1975; Minghetti et al., 1986) and a molecular weight of 66.5 kDa (Putnam, 1984) with great interspecies similarities despite the variability in some residues (Brown, 1976; Majorek et al., 2012). It is the most abundant protein in mammals, with almost 60% of the total amount of plasma proteins, and a physiological concentration varying between 3.0 to 5.0 g/dL (500 μ M–750 μ M, mean value $\sim$ 600 μ M or $\sim$ 4.5 % w/w) (Peters Jr., 1996). It has acidic characteristics, a negative net charge (-15 for humans) at the physiological pH of 7.4, and an isoelectric

* Corresponding author.

E-mail address: michel.bteich@umontreal.ca.<https://doi.org/10.1016/j.heliyon.2019.e02879>

Received 20 October 2018; Received in revised form 4 January 2019; Accepted 15 November 2019

2405-8440/© 2019 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

point of 4.7 (Peters Jr., 1996; Rothschild et al., 1988).

The 17 conserved disulfide bridges of cysteine (Cys) bonds ensure the flexibility of its conformation (normal or N state) (Weber, 1975) and the stability of its structure at pH 7.4 (Markus and Karush, 1957), even in extreme conditions, noticeably in all mammalian serum ALB (Majorek et al., 2012). These bridges contribute in prolonging its biological lifetime (Peters Jr., 1996), and in conserving the three-dimensional structure among different species (Nurdiansyah, Rifa'i, & Widodo, 2016). The neonatal Fc receptor (FcRn) may also have a role in prolonging the lifespan of ALB (Chaudhury et al., 2003), as it binds to ALB (domain III) in a pH-dependent internalization process of the complex with immunoglobulin G (IgG) (Andersen et al., 2006; Goebel et al., 2008; Sand et al., 2014). Thus, FcRn receptor plays a fundamental role in homeostatic regulation of both IgG and ALB, and in helping these proteins escape intracellular degradation by recycling them back to the systemic circulation (Chaudhury et al., 2003; Sand et al., 2014).

The disulfide bonding patterns give ALB a heart-like crystal structure in humans (3.2 Å) (He and Carter, 1992) and resolved at higher resolution (2.5 Å) (Curry et al., 1998). It has about 67% of α -helices, 10% β turns, but no β -sheet (Peters Jr., 1996). The flexibility of ALB allows for the binding with a high affinity of a wide variety of xenobiotics at its two primary sites: Sudlow I and II (Fanali et al., 2012; Peters Jr., 1996; Sudlow, Birkett, & Wade, 1975, 1976). Sudlow's site I is known as the warfarin-azapropazone binding cleft (Fehske et al., 1982), while Sudlow's site II is the ibuprofen-diazepam (or indole/benzodiazepine) binding cleft (Ascenzi and Fasano, 2010; Fanali et al., 2012; Fasano et al., 2005).

The structural representation contains three homologous domains (Brown, 1976; Dockal et al., 1999): I (25–222 AA), II (223–414 AA), and III (415–609 AA) with nine double loops repeated in triplet fashion (Peters Jr., 1996; Rothschild et al., 1988). Double loops 1–2, 4–5, and 7–8 are grouped as subdomains IA, IIA, and IIIA, respectively. Single loops 3, 6, and 9 are represented by subdomains IB, IIB, and IIIB, respectively. In each domain consisting of about 10 α -helices, there is a pair of helicoidal subdomains named A (6 α -helices) and B (4 α -helices) that are connected by random coils (Ascenzi and Fasano, 2010). Interactions in-between domains favour an asymmetrical environment for allosteric ligand binding (Curry et al., 1998; Fasano et al., 2005; Peters Jr., 1996).

ALB is characterized by its two hydrophobic cavities in site I (subdomain IIA) and site II (subdomain IIIA), with polar residues in the inner surroundings and at the entrance of the two pockets (Ghuman et al., 2005). Bulky heterocyclic anions preferentially bind to the first main site, and the second is preferred by aliphatic and aromatic carboxylates (Ascenzi and Fasano, 2010). Although a third major binding site (subdomain IB, or lidocaine site) has been recently suggested to exist by Zsila (2013); further studies on binding with a high affinity to this site are needed before ALB can be represented as a conventional three-site model.

ALB displays up to seven binding sites with different affinities for free long-chain fatty acids (FAs) which may be associated to a local conformational change of the secondary structure (e.g. palmitic acid, oleic acid and arachidonic acid) (Fanali et al., 2012; Ghuman et al., 2005). The FA1 to FA7-occupied sites accommodate the binding of endogenous and exogenous substances to the primary sites I and II (Ascenzi and Fasano, 2010; Fanali et al., 2012). This kind of accommodation would increase the affinity of the ligand, making it a cooperative interaction (Lehman-McKeeman, 2013). Conversely, some studies reported a possible competition between FAs and some ligands (Chakrabarti, 1978), implicating a possible displacement from the binding site due to allosteric modulation (Ascenzi and Fasano, 2010; Fasano et al., 2005). Because the binding of small ligands might not completely fill the hydrophobic pocket in Sudlow's site I; the site is predisposed to the insertion of water molecules, and thus the polar residues by hydrogen bonding (H-bonds) (Curry, 2009; Ghuman et al., 2005). This effect influences the adaptability of the site to the binding interaction. Multiple monolayers of water molecules

reversibly bond their hydrogen atoms to the residues at the surface of the protein and navigate along with it in the extracellular space (Peters Jr., 1996).

ALB has many prominent physiological functions (Peters Jr., 1996). It is a leading carrier and a depot in blood circulation for endogenous substances (e.g. bilirubin, FAs, hormones, bile acids, etc.) (Fanali et al., 2012; Kurtzhals et al., 1997; Roda et al., 1982), exogenous substances (e.g. heavy metals Hg, Cd and Pb, drugs, contaminants) (Li et al., 2007) and other essential ligands (e.g. transition metal ions Zn^{2+} , Ca^{2+} , nitric oxide, metallothionein, vitamins, haem) (Ascenzi and Fasano, 2009; Bal et al., 2013; Hou et al., 2008; Quiming et al., 2005; Sadler and Viles, 1996). ALB regulates the colloidal osmotic pressure with its high concentration in plasma by keeping the blood within vessels. It has enzymatic properties that are useful in metabolism and detoxification of exogenous and endogenous ligands (Fitzpatrick and Wynalda, 1983; Kragh-Hansen et al., 2002; Yang et al., 2002). ALB has a buffering capacity of the blood but to a lesser extent than haemoglobin (Pettifer, 2003). ALB has the largest thiol pool in plasma (Turell et al., 2013). It plays an antioxidant role (Hu, 1994) as it scavenges reactive oxygen species and reactive nitrogen species (Quinlan et al., 2005). This scavenging activity of ALB is largely dependent on the redox state of the residue Cys34 (Anraku et al., 2013; Stamler et al., 1992).

ALB is a negative acute-phase protein (Bowman, 1993), as its concentration decreases in case of inflammation under the influence of cytokines (IL6, IL1 and TNF α) (Kmiec, 2001). Thanks to ALB's many appreciable characteristics, *inter alia*, *in vivo* half-life (~19 days), stability, and binding versatility (Peters Jr., 1996); medical and pharmaceutical applications that include ALB in *in-vitro* and *in vivo* conditions (e.g. nanomaterials, biomarkers, toxicokinetics, preclinical, etc.) are becoming numerous with technological advancements in health science disciplines (e.g. genetics, oncology, nanotechnology, biochemistry, toxicology, therapeutics, etc.). For further exploration of the use of ALB, examples are given in two reviews by Peters Jr. (1996) and Otagiri and Chuang (2016).

2.2. Alpha-1-acid glycoprotein

The plasma protein AGP, also known as orosomucoid (ORM), is a glycosylated single chain protein (Fournier, Medjoubi-N, & Porquet, 2000; Kremer et al., 1988; Schmid, 1950, 1989; Weimer et al., 1950). Like ALB, AGP is mainly synthesized (10 mg/kg/day) (Lentner, 1984) and catalysed in the liver (Sarcione, 1963). However, asialo- or agalacto-AGP is internalized into hepatocytes using a specific membrane asialoglycoprotein receptor (ASGP-R) for its degradation (Taguchi et al., 2013). This process is only possible when its binding site is vacant and after AGP's conformation changes (Meijer and Nijssen, 1991; Meijer and van der Sluijs, 1989). Its half-life is 2–3 days, so a high AGP concentration is easily cleared from the body even after its induced synthesis (Brée et al., 1986). Unlike ALB, AGP is scarce in plasma as it accounts for only 3% of plasma proteins. In healthy adults, the physiological concentration varies between 0.05 to 0.1 g/dL (10 μ M–20 μ M; mean value ~15 μ M) (Kremer et al., 1988); some references even give a maximum normal value of 0.140 g/dL (31 μ M). The plasma concentration of AGP increases with age and is sex-dependent (Israili and Dayton, 2001). AGP is an acidic (pKa = 2.6) and highly soluble protein in water and other polar organic solvents (Schmid, 1989). Its net charge is negative and depends on the nature of its carbohydrate entities. Its isoelectric point varies between 2.8 and 3.8, at the physiological pH of 7.4 (Fournier et al., 2000).

In humans, the mature form of AGP consists of 183 AA. It has a molecular weight of about 44 kDa (Kremer et al., 1988) (or 41–43 kDa according to Hocheppied et al. (2003)). The AGP protein consists of about 59% peptide residues and 41% carbohydrates - of which about 11% are sialic acids (or 12% according to Hocheppied et al. (2003)). This high sialic content contributes to the negative charge on its surface (Kremer et al., 1988; Schmid et al., 1977) and determines the nature of interactions that this glycoprotein can have with biological membranes.

There are five structurally heterogeneous carbohydrate entities (five N-glycans) with mono-, bi-, tri-, and tetra-antennary glycans covalently linked to five asparagine (Asn) residues, which form N-glycosylation sites (Asn-15, Asn-38, Asn-54, Asn-75, Asn-85) to the most active gene ORM1 (variant F1*S) between the two main genes of AGP (i.e. ORM1 and ORM2) (Dente et al., 1987; Fournier et al., 2000; Taguchi et al., 2013; Yoshima et al., 1981; Yuasa et al., 1997).

Physiological (e.g. inflammation vs healthy status) and environmental conditions influence the variability in glycosyl branching (Gornik et al., 2009). The heterogeneity of glycosylation does not only influence the binding of xenobiotics but also affects the kinetics of the protein itself (half-life, uptake, and catabolism) (Fernandes et al., 2015; Gross et al., 1989). The carbohydrate moiety contributes to this protein's stability, native conformational structure, and solubility (Bürgi, 1989). This moiety of asialo-AGP interacts with plasma membranes and receptors (i.e. ASGP-R), and is internalised by endosomes under lysosomal action or recycled to the extracellular space (Meijer and van der Sluijs, 1989; Taguchi et al., 2013).

There are two main variants (F1*S and A) implicated in high affinity binding (Eap et al., 1988). The difference in AA residues between these variants is due to 21 AA substitutions, which affects the affinity and the stereoselectivity of the binding to AGP (Dente et al., 1987; Fitos et al., 2010; Hervé et al., 1998; Herve et al., 1993). The variant F1*S is predominant (Montiel et al., 1990), and in normal conditions its expression is two-to three-fold higher than variant A (Yuasa et al., 1997).

AGP contains two disulfide bonds in all its main allelic variants that sustain the stability of its secondary structure (Kremer et al., 1988; Schmid et al., 1973). These bonds, like sialic acids, contribute to AGP's potential interactions with biomembranes (Nishi et al., 2006). The native protein consists of 15% α -helices, 41% β -sheets, 12% β -turns, 8% bends, and 24% unordered structure at pH 7.4 (Kopecký et al., 2003). The α -helical content may increase upon disulfide reduction and in the presence of biomembranes (Nishi et al., 2006). AGP only has one primary saturable site that could be for some ligands of high-affinity and low-capacity characteristics formed by the tertiary structure (Müller, 1989), and located in the hydrophobic crevice consisted of three lobes (Maruyama et al., 1990; Schonfeld et al., 2008). While many other sites with different capacities and low affinities exist, only the main site is of clinical relevance (Müller, 1989).

Although the biological functions of AGP are not clear, it is worth noting a few of its physiological activities. Like ALB, AGP is a leading plasma protein in transporting various endogenous (e.g. serotonin, platelet activating factor, histamine, melatonin) and exogenous ligands (e.g. drugs and contaminants) (Baumann et al., 1989; Fournier et al., 2000; Israili and Dayton, 2001). It is a positive acute-phase protein (Bowman, 1993; Kushner, 1982). It is classified as a member of the immunocalin family (i.e. lipocalin subfamily), as it has an anti-inflammatory and immunomodulation role in all mammals (Bennett and Schmid, 1980; Hochebied et al., 2003). It has an inhibitory effect on immune cells (e.g. lymphocyte T) and platelet aggregation, and it causes the induction of certain cytokines (Hochebied et al., 2003). It could be used as an effect biomarker (Routledge, 1989), and to serve in prediction of all-cause mortality (Fischer et al., 2014). However, some authors argue that AGP is not a better marker of short- or long-term mortality risk than the more commonly used biomarkers IL-6 and CRP (Singh-Manoux et al., 2017). This could be true since in cases of acute inflammation in humans, plasma levels of CRP may rapidly rise by about 1000-fold or more (Black et al., 2004).

The increase of AGP's physiological concentration is species dependent. It may increase more than four times the normal concentration (1 g/L) in humans and from 0.2 g/L up to 100-fold in rats (Baumann and Held, 1981; Fournier et al., 2000; Hochebied et al., 2003) in case of pathologies (e.g. myocardial infarction, nephritis), inflammation, infection, or cancer (Huang and Ung, 2013; Israili and Dayton, 2001). Organs other than the liver and cells other than hepatocytes (i.e. leukocytes) can synthesize AGP, especially under the action of cytokines (IL-1 β , IL-6),

TNF α , and glucocorticoids (Baumann et al., 1989; Israili and Dayton, 2001; van Dijk et al., 1991), or in response to various stress stimuli (e.g. infection, burn, surgery, trauma, or cancer) (Israili and Dayton, 2001; Jackson et al., 1982; Kremer et al., 1988; Piafsky, 1980). In the case of acute phase reactions, the normal ratio between the two main variants (F1*S and A) increases more than three-fold, marking a significant production of the F1*S variant (Taguchi et al., 2013). This variation could be about eight times higher in case of lymphoma, melanoma, and ovarian cancer (Taguchi et al., 2013). In cancer biomonitoring, specific glycans on the surface of AGP could be used as biomarkers in the progression of breast cancer (Abd Hamid et al., 2008).

3. Amino acids in high affinity binding sites

The affinity binding is a descriptive characteristic estimated for a bundle of amino acids, in a site of a plasma protein, that interacts and accommodates ligands to bind into binding cavities. In plasma proteins, some residues have a more important role than others for binding ligands in high-affinity binding cavities, and this discrepancy in importance depends, *inter alia*, on the functional groups of each ligand. Also, some changes in residues may occur and significantly modulate the inner composition of high-affinity binding pockets and their peptide outer surroundings. For example, polar AAs may be replaced with neutral or hydrophobic ones, or positive residues may be replaced with negative ones and vice versa. Consequently, the alteration of nucleotides and peptides influences the extent of binding to plasma proteins (Huang and Ung, 2013; Otagiri and Chuang, 2016). To better understand this influence, the composition in AAs of high-affinity binding sites of most frequent variants for human ALB and AGP is discussed next (see Tables 1 and 2).

3.1. Mature ALB in humans

The free Cys34, known for its antioxidant role, is well conserved in humans (position 58 in native ALB). About 70–80% of Cys34 in plasma contains a free sulfhydryl group, while the other 25% forms a disulfide bond with small sulfhydryl compounds, such as cysteine, homocysteine, or glutathione (Oettl and Stauber, 2007). Another well-conserved residue in ALB is Trp214. It is situated in a major interdomain cluster of hydrophobic residues (position 238 in native ALB), and precisely in a conserved sequence of loop 4 (binding pocket of Sudlow I). This hydrophobic residue is important, just like disulfide bridges, for holding together the two halves of the heart-shaped ALB (Carter and Ho, 1994). The absorption of UV light by ALB is particularly attributed to Trp214, which is quite appreciated as a fluorescent residue in binding studies for the measurement of thermodynamic parameters (e.g. fluorescence quenching) (Tayeh et al., 2009).

In subdomain IIA of the mature ALB, site I has the voluminous cavity and it is constituted from 177 AA to 291 AA. In subdomain IIIA, site II has the smaller cavity and it is constituted from 367 AA to 491 AA. The residues most involved in binding ligands to the two high-affinity binding cavities of human ALB, other than Trp214 and Cys34, are presented in Table 2. Each binding site includes a hydrophobic cavity with distinct polar or ionic residues within it or its surroundings. Therefore, hydrophobic, polar, and electrostatic interactions play a key role in determining the affinity of ligands for both sites I and II. The interior Site I's pocket cavity is predominantly hydrophobic delimited by residues Trp214, Leu219, Phe223, Leu238, His242, Leu260, Ile264, Ser287, Ile290, and Ala291; so mainly hydrophobic interactions are dominant (Yang et al., 2014). The site also contains two clusters of polar or ionic residues, an inner one towards the bottom of the pocket composed of Tyr150, His242, and Arg257; and an outer strictly-cationic cluster at the cavity entrance composed of Lys195, Lys199, Arg218, Arg222 (Ghuman et al., 2005). Such placement of residues orchestrates binding of aromatic compounds with centrally located negative or electronegative features (Curry, 2009). Thus, bulky heterocyclic anions preferentially bind to site

Table 1

Summary of distinct characteristics of ALB and AGP in humans.

Characteristics	Human plasma proteins	
	ALB ^a	AGP ^b
Gene (allelic variants); chromosome location	1 gene ALB (number of variants depends on ethnic group); Located on chromosome 4 (4q11-q13)	2 genes with main variants and 21 amino acid differences: ORM1 or AGP-A (variants F1, F2 and/or S), collectively referred as F1*S; ORM2 or AGP-B/B' (variant A) with different drug properties; Located on human chromosome 9 (9q31–34.1)
Native polypeptide sequence (N-terminal signal peptide; propeptide; mature protein)	609 AA (18 AA; 6 AA; 585 AA)	201 AA (18 AA; 183 AA)
Family	Albumin superfamily	Lipocalin subfamily (immunocalin family)
Synthesis	Synthesized by the liver (13.3 g/day) with mild extrahepatic synthesis	Synthesized by the liver (20mg/Kg/day) with extrahepatic synthesis in normal conditions and increased synthesis in case of inflammation, infection or disease
Half-life	Around 19 days	At least 2–3 days, around 5 days
Structure	67% of α -helices, 10% β turns, but no β -sheet	15% α -helices, 41% β -sheets, 12% β -turns, 8% bends and 24 % unordered structure (α -helical content may increase upon disulfide reduction and in the presence of biomembranes)
Glycosidic residues	No, 100% peptide residues. In the case of pathology, some glycosidic residues may be present on the protein	- Yes, 59% peptide residues and 41% carbohydrates, of which about 11% are sialic acids, 14% neutral hexoses, 14% hexosamine, and 1% fructose. - Five carbohydrate entities (N-glycans) covalently linked to Asn residues (Asn15, Asn38, Asn54, Asn75, Asn85) - Internalization after binding to ASGP-R at the sinusoidal for its degradation in endosomes
Internalization mechanism	Internalisation that includes a FcRn- IgG- ALB complex for its degradation or recycling Other glycoprotein receptors on LSEC (e.g. gp60)	- Other membrane receptors may be implicated
Concentration	3.0–5.0 g/dL (500 μ M–750 μ M); 60% of total plasma proteins	0.05 and 0.1 g/dL (10 μ M–20 μ M); 3% of total plasma proteins
Main binding sites	- Two primary sites with high affinity, low capacity; secondary sites with low affinity - Seven Fatty acids' sites	One primary site with high affinity and low capacity; many secondary sites with low affinity (five sites for endogenous and some drugs, one site for drugs and the other for steroids)
Domains	Domain I (25–222 AA), domain II (223–414 AA) and domain III (415–609 AA); secondary and tertiary structures	Variant F1*S (3 lobes; main lobe I and two smaller lobes II and III) and variant A (2 lobes); secondary and tertiary structures
Net charge	(-15) at pH 7.4	Depends on glycosylation (up to 20 types of glycans structures)
Isoelectric point	4.7	Between 2.8 and 3.8 for AGP with high content of sialic acid
Main roles	- Negative acute-phase protein; its concentration decreases significantly - Antioxidant activity, protecting cells and tissues - Predominant binding protein for transport and depot	- Activities are dependent on the carbohydrates' composition - Positive acute-phase protein; its concentration increases significantly - Immunomodulatory activities - Antioxidant activity, protecting cells (e.g. erythrocytes) and tissues against septic shock and ischemia, inhibition of TNF α - Direct activities of AGP against bacterial pathogens - Sensitizing effect (e.g. acute colitis) - Predominant binding protein for transport and depot - Inhibition of platelet aggregation - Basic (cationic) and neutral characteristics - Stereoselective Binding depends on glycosylation and variant type - F1*S binds a wider range of drugs
Main binding and common high Affinity of xenobiotics with	Acidic (anionic) characteristics	- Two disulfide bonding (C5–C147; C72–165) - Three Tryptophan (W25, W122 and W160) - Electrostatic, polar and hydrophobic interactions with ligands or membrane phospholipids may induce conformational changes
Notable features for PTMs	- 17 disulfide bonding; free sulfhydryl group of Cys34; - one Tryptophan (W214) - Electrostatic, polar and hydrophobic interactions with ligands or membrane phospholipids may induce conformational changes	- Effect biomarker for inflammation, cancer and various pathologies - Ratio of AGP to prealbumin biomarker for carcinoma of the prostate - Biomarker for all-cause mortality
Biomarker	- Cys34 (antioxidant role and ROS, RNS scavenger) - Low ratio of ALB to globulin is a biomarker for several types of cancer (neck, breast, prostate, lung, gastric etc.) - Biomarker for all-cause mortality	- Plasma protein concentration itself (regulation and feed-back) - Low levels in foetus, infants and elderly - Decrease during aging - Increase of AGP under the effect of cytokines and various diseases - Increase in case of burns, infections, cancer, inflammation (e.g. rheumatoid arthritis), and other stress stimuli - Decrease of AGP levels in case of liver disease, use of oral contraceptive, and in pregnancy - De novo mRNA synthesis induces the synthesis of AGP in case of inflammation or diseases
Main factors influencing the binding	- Plasma protein concentration itself (regulation and feed-back) - Low levels in foetus, infants and elderly - Decrease during aging - Decrease of ALB under the effect of cytokines and in case of diseases (e.g. liver) - Decrease in case of burns, infections, cancer, inflammation (e.g. rheumatoid arthritis), pregnancy and other stress stimuli - Analbuminemia: extremely low concentration if there is no expression of mRNA due to mutations	

AA amino acids; **AGP** alpha-1-acid glycoprotein; **ALB** albumin; **Asn** asparagine; **ASGP-R** asialoglycoprotein receptor; **Cys** cysteine; **IgG** immunoglobulin G; **LSEC** liver endothelial cells; **ORM** orosomucoid; **PTMs** post-translational modifications; **ROS** reactive oxygen species; **RNS** reactive nitrogen species.

^a (Ascenzi and Fasano, 2009; Fanali et al., 2012; Fasano et al., 2005; He and Carter, 1992; Kragh-Hansen, 2016; Otigiri and Chuang, 2016; Peters Jr., 1996).

^b (Baumann et al., 1989; Fournier et al., 2000; Hochepled et al., 2003; Israilli and Dayton, 2001; Kremer et al., 1988; Piafsky, 1980; Piafsky and Borga, 1977; Schmid et al., 1977; Schonfeld et al., 2008; Taguchi et al., 2013).

Table 2

Summary of most involved amino acids in high-affinity binding sites.

Human ALB ^a				Human AGP ^c	
Sudlow's site I: warfarin-binding site (subdomain IIA)		Sudlow's site II: indole/benzodiazepine site (subdomain IIIA)		One main site	
Helix	Residue	Helix	Residue	Stranded β -barrel	Residue
H1	- Asp187 - Lys190 - Lys195 - Lys199	H1	- Pro384 - Leu387 - Ile388 - Asn391 - Cys392 - Phe395	BB1	- Tyr27
H2	- Phe211 - Trp214 - Ala215 - Arg218 - Leu219 - Arg222 - Phe223	H2	- Arg410 - Tyr411 - Lys414	BB2	- Phe49 - Phe51
H3	- Leu234 - Leu238 - His242	H3	- Leu430 - Val433 - Cys438	BB3	- Glu64 - Leu62 - Arg68
H4	- Arg257 - Leu260 - Ala261 - Ile264	H4	- Ala449 - Glu450 - Leu453	BB4	- Leu79 - Val81
H5	-	H5	-	BB5	- Ile88 - Ser89 - Arg90 - Val92 - His97
H6	- Ile290 - Ala291	H6	- Arg485 - Ser489	BB6	- His100 - Leu101 - Tyr110 - Leu112 - Ala113 - Phe114
None ^b	- Arg114 - Tyr150 - Glu292	-	-	BB7	- Tyr127 - Ile13 - Leu18 - Ser40 - Asp115 - His172
				BB8 Helices	

Ala alanine; **AGP** alpha-1-acid glycoprotein; **ALB** albumin; **Arg** arginine; **Asp** aspartic acid; **BB** β -barrel; **Glu** glutamic acid; **H1-6** Helix 1–6; **His** histidine; **Ile** isoleucine; **Leu** leucine; **Lys** lysine; **Ser** serine; **Trp** tryptophan; **Tyr** tyrosine; **Phe** Phenylalanine; **Pro** proline.

^a Adapted from *Peters Jr. (1996)* page 37. The information for human ALB is completed from *Ascenzi and Fasano (2010)*, *Curry (2009)*, *Hein et al. (2010)* and *Ghuman et al. (2005)*.

^b Residues that are not found in a helix nor in a β sheet of ALB site I.

^c Information for AGP-F1*S in humans is found in *Nishi et al. (2006)* and *Taguchi et al. (2013)*. The same important AAs constituting and surrounding AGP's main binding site can be viewed in the 3D crystal structure of human AGP (pdb 3KQ0) at: <http://www.rcsb.org/pdb/ngl/ngl.do?pdbid=3KQ0&preset=validationReport>.

I between apolar Leu238 and Ala291 in the centre of the pocket.

Regarding the site II, only one main cluster of polar or cationic residues is near the pocket entrance which makes it more exposed to the solvent; it is composed of Arg410, Tyr411, Lys414, and Ser489. Therefore, a combination of hydrophobic, hydrogen bonding, and electrostatic interactions play a crucial role in preferentially binding aliphatic and aromatic carboxylates with peripherally located negative or electronegative features to site II (*Curry, 2009*).

Additionally, there is a third unique site formed by residues from subdomain IB facing the central interdomain crevice (*Zsila, 2013*). For example, the binding of lidocaine (cationic drug) to this site is mainly the result of cation- π interaction with Arg114, polar interaction with Lys190, and electrostatic attraction to Asp187 (*Hein et al., 2010*). According to *Carter and Ho (1994)*, other potential salt bridges exist between

Lys190-Glu425; Lys205-Glu465; Asp451-Arg218; and Asp187-Lys432-Arg521; with other hydrophobic interactions that involve the interdomain cluster (Phe206, Leu481, Val482, Trp214, Leu347, Val343, Val344, Leu331, Ala217, and Tyr452) —these should be considered when assessing ALB binding.

Plasma proteins of distinct species have antigenic variants, which induce immunological reactions. According to *Majorek et al. (2012)*, subdomain IB has two regions with significant differences between human and bovine ALB. Residues in these two regions are surface-exposed and may be recognized as epitopes by human immunoglobulins (e.g. in allergies). Other species such as rabbits have different regions that can induce the cross-reactivity of alloantibodies to its antigenic variants.

3.2. Mature AGP in humans

Human AGP's sequence is less conserved than that of human ALB. In the solely high-affinity and low-capacity site of AGP, there are three distinct lobes (*Nishi et al., 2006*). The deep main lobe I is voluminous and apolar; it provides sufficient space to accommodate ligands with hydrophobic characteristics. The entrance of the cavity has two positively charged side residues, Arg68 and Arg90, which favour interactions with ligands having polar and negative characteristics. The entrance of human AGP-variant A is narrower than that of F1*S (*Taguchi et al., 2013*). Thus, the variant F1*S binds a larger variety of ligands.

AGP's lobe I is approximately 18 Å deep and is constituted of Tyr27, Phe49, Phe51, Leu62, Leu79, Ile88, Leu101, Tyr110, Leu112, and Tyr127 (*Table 2*). Other apolar residues Ile13, Leu18, and Val81 form its bottom. The hydrophobic lobe I in AGP is located between two negatively charged smaller lobes (lobes II and III). Because the overall surface of AGP is negatively charged, it is highly soluble in the extracellular space. Sialic acids and carbohydrate moiety contribute to the negative charge of glycosylated AGP, consequently attracting xenobiotics with positive charges at pH 7.4. The negative charge of peptide sequence is sufficiently exposed in non-glycosylated human AGP due to the presence of nine Asp and eight Glu side chains that surround the β -barrel (*Nishi et al., 2006*). The negative charge of lobe II is due to residue Glu64 in its lower part, while the negative charge in lobe III is due to Asp115. All these residues are responsible for the strong binding of basic-characteristic ligands into AGP pockets.

4. Differences in the plasma protein binding

4.1. Factors related to the structural characteristics of the plasma proteins

Many factors could be behind the differences in the binding kinetics of drugs to the same plasma protein or to different plasma proteins. As presented in section 2, these factors could be related, *inter alia*, to the health status of the individual, the species (e.g. human, rat or bovine), the medium conditions (e.g. pH, temperature, salinity and presence of FAs), the structural characteristics, the physiological abundance, the polymorphism and the variants of the plasma proteins, and to the physicochemical of the drugs.

In this review, there is an emphasis on the structural and molecular characteristics (i.e. glycosylated/non-glycosylated forms (*Wu et al., 2018*), the charge/polarity of residues and the molecular volume of the site). In studies on binding kinetics, the type of ligands (i.e. base, acid or neutral), the type of molecular attractions and the values of their affinity coefficients to the binding cavities depend mainly on the structural characteristics of ALB and AGP. Particularly, the ionic, polar and hydrophobic clusters constituting high-affinity binding pockets and their surroundings play a major role in plasma protein binding for both proteins. For example, the sites of ALB and AGP have hydrophobic characteristics which make these pockets propitious for binding organic compounds (*Ajmal, Nusrat, et al., 2017a; Hanada, 2017; Yang et al., 2014*).

The in-site interactions would depend on the functional groups of the ligands. Therefore, acidic, base or neutral molecules may have either hydrophobic or hydrophilic characteristics (e.g. drugs, organic contaminants and heavy metals). Despite their differences in functional groups, the distinct molecules may bound to the same site if the accommodating-bundle of residues is found. For example, the drugs that preferentially bind to site II may be an acidic molecule like ibuprofen (Ascenzi et al., 2009), or a basic molecule like clofazimine (Ajmal, Zaidi, et al., 2017b). As presented in section 3, the charged residues found in binding cavities for both proteins influence the extent of binding of each ligand. It is most likely possible that the charged residues on the surfaces of both proteins may also have a role in attracting ligands with opposite charges towards sites. On their surfaces, an ALB molecule is rich in clusters of charged residues (Lys and Arg) which attracts acidic probes, while AGP has glycosyl groups that mainly attract base probes and influence their binding affinities (Fernandes et al., 2015). Thus, base drugs may have high affinities for AGP (Asp and Glu residues), and most probably low affinities for ALB (Lys and Arg). Conversely, acidic drugs may have higher affinities to ALB than to AGP.

The computational methods and molecular modelling are powerful tools to estimate protein binding affinity and to simulate the potential interactions in the binding pockets based on the physicochemical properties of compounds, and of the residues involved in the plasma protein binding (Wanat et al., 2018). These tools may also give an idea on how different the binding of a ligand to human ALB from its binding to AGP and which protein-ligand complex is more stable under the same experimental conditions, particularly that the residues involved in the molecular interactions are not the same for the two proteins (Ajmal, Nusrat, et al., 2017a; D. P. Yeggoni, Manidhar, Suresh Reddy and Subramanyam, 2016; Daniel Pushparaju Yeggoni, Rachamalla and Subramanyam, 2016). Consequently, the interactions simulated between functional groups of the ligand and the residues of the plasma proteins are distinct which could be interesting to explore a priori of PK/PD studies in different species.

4.2. Post-translational modifications

The plasma proteins go through post-translational modifications (PTMs) which may affect molecular interactions between residues in binding residues and their ligands. PTMs are biochemical mechanisms that are crucial for normal cell differentiation (Wang et al., 2014), and during which residues at the side chains covalently modify their properties (Walsh et al., 2005). The PTMs may thus affect binding of ligands to plasma protein (i.e. stereoselective allosteric binding) and/or may be used as biomarkers for some diseases (e.g. glycation of ALB) (Maciazek-Jurczyk et al., 2018). Therefore, we also emphasize the consideration of PTMs of plasma proteins (e.g. disulphide bridges and N-linked glycosylation) in binding and PK/PD studies. Their inclusion could further guide *in vitro* and *in vivo* experiments (Audagnotto and Dal Peraro, 2017), computational approaches and molecular docking. The most common types of PTMs are phosphorylation, acetylation, N-linked and O-linked glycosylation, methylation, and ubiquitylation (Walsh et al., 2005; Wang et al., 2014). PTMs can be classified according to the type of residue (i.e. Lys, Cys, Asn, Arg, Ser, Thr and Tyr); the category of the enzyme making one of the two covalent modifications (i.e. additions, cleavage); and the extent of reversibility of the modification.

5. Summary

Both plasma proteins ALB and AGP have key roles in the transporting and storing of drugs and contaminants in plasma. Structural and molecular characteristics of ALB and AGP may have a direct influence on binding kinetics of xenobiotics (i.e. drugs and contaminants). Change in binding kinetics would cause some alterations in drugs disposition (i.e. distribution, uptake, clearance) and efficacy. Thus, understanding the

differences in the functions and the structural and molecular characteristics of these plasma proteins, and addressing the changes in their residues are necessary for interdisciplinary research in PK/PD that is gaining place in the 21st century. For qualitative/quantitative modelling purposes, researchers designing new preclinical and clinical studies should address the intra- and interspecies differences (i.e. type of molecular attractions) not only in plasma protein binding extent, but more particularly in the composition of binding cavities and their peptide surroundings.

Declarations

Author contribution statement

All authors listed have significantly contributed to the development and the writing of this article.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interest statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

Acknowledgements

This review makes a part of the author's Ph.D. thesis. The author acknowledges the support given by his main supervisor Dr. Sami Haddad and co-supervisor Dr. Patrick Poulin.

References

- Abd Hamid, U.M., Royle, L., Saldiva, R., Radcliffe, C.M., Harvey, D.J., Storr, S.J., Rudd, P.M., 2008. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. *Glycobiology* 18 (12), 1105–1118.
- Ajmal, M.R., Nusrat, S., Alam, P., Zaidi, N., Khan, M.V., Zaman, M., Khan, R.H., 2017. Interaction of anticancer drug clofarabine with human serum albumin and human alpha-1 acid glycoprotein. Spectroscopic and molecular docking approach. *J. Pharm. Biomed. Anal.* 135, 106–115.
- Ajmal, M.R., Zaidi, N., Alam, P., Nusrat, S., Siddiqi, M.K., Badr, G., Khan, R.H., 2017. Insight into the interaction of antitubercular and anticancer compound clofazimine with human serum albumin: spectroscopy and molecular modelling. *J. Biomol. Struct. Dyn.* 35 (1), 46–57.
- Andersen, J.T., Dee Qian, J., Sandlie, I., 2006. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. *Eur. J. Immunol.* 36 (11), 3044–3051.
- Anraku, M., Chuang, V.T., Maruyama, T., Otagiri, M., 2013. Redox properties of serum albumin. *Biochim. Biophys. Acta* 1830 (12), 5465–5472.
- Ascenzi, P., di Masi, A., De Sanctis, G., Coletta, M., Fasano, M., 2009. Ibuprofen modulates allosterically NO dissociation from ferrous nitrosylated human serum heme-albumin by binding to three sites. *Biochem. Biophys. Res. Commun.* 387 (1), 83–86.
- Ascenzi, P., Fasano, M., 2009. Serum heme-albumin: an allosteric protein. *IUBMB Life* 61 (12), 1118–1122.
- Ascenzi, P., Fasano, M., 2010. Allostery in a monomeric protein: the case of human serum albumin. *Biophys. Chem.* 148 (1–3), 16–22.
- Audagnotto, M., Dal Peraro, M., 2017. Protein post-translational modifications: in silico prediction tools and molecular modeling. *Comput. Struct. Biotechnol. J.* 15, 307–319.
- Bal, W., Sokolowska, M., Kurowska, E., Faller, P., 2013. Binding of transition metal ions to albumin: sites, affinities and rates. *Biochim. Biophys. Acta* 1830 (12), 5444–5455.
- Baumann, P., Eap, G.B., Müller, W.E., Tillement, J.P., 1989. Alpha1 – Acid Glycoprotein (Genetics, Biochemistry, Physiological Functions and Pharmacology). Alan R. Liss, New York.
- Baumann, Held, W.A., 1981. Biosynthesis and hormone-regulated expression of secretory glycoproteins in rat liver and hepatoma cells. Effect of glucocorticoids and inflammation. *J. Biol. Chem.* 256 (19), 10145–10155.

- Bennett, M., Schmid, K., 1980. Immunosuppression by human plasma alpha 1-acid glycoprotein: importance of the carbohydrate moiety. *Proc. Natl. Acad. Sci.* 77 (10), 6109–6113.
- Black, S., Kushner, I., Samols, D., 2004. C-reactive protein. *J. Biol. Chem.* 279 (47), 48487–48490.
- Bowman, B.H., 1993. *Hepatic Plasma Proteins: Mechanisms of Function and Regulation*. Academic Press Inc, California : USA.
- Brée, F., Houin, G., Barré, J., Moretti, J.-L., Wirquin, V., Tillement, J.-P., 1986. Pharmacokinetics of intravenously administered 125I-labelled human α 1-acid glycoprotein. *Clin. Pharmacokinet.* 11 (4), 336–342.
- Brown, J.R., 1976. Structural origins of mammalian albumin. *Fed. Proc.* 35 (10), 2141–2144.
- Bürgi, W., 1989. The biological role of the carbohydrate moiety of human plasma glycoproteins. In: Baumann, P., Eap, C.B., Müller, W., Tillement, J.P. (Eds.), *Prog Clin Biol Res*, 300. ALAN R. LISS, New York: USA, pp. 23–45.
- Carter, D.C., Ho, J.X., 1994. Structure of serum albumin, 45, 153–203.
- Chakrabarti, S.K., 1978. Cooperativity of warfarin binding with human serum albumin induced by free fatty acid anion. *Biochem. Pharmacol.* 27 (5), 739–743.
- Chaudhury, C., Mehnaz, S., Robinson, J.M., Hayton, W.L., Pearl, D.K., Roopenian, D.C., Anderson, C.L., 2003. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. *J. Exp. Med.* 197 (3), 315–322.
- Curry, S., 2009. Lessons from the crystallographic analysis of small molecule binding to human serum albumin. *Drug Metab. Pharmacokinet.* 24 (4), 342–357.
- Curry, S., Mandelkow, H., Brick, P., Franks, N., 1998. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. *Nat. Struct. Biol.* 5 (9), 827–835.
- Dente, L., Pizzo, M.G., Metspalu, A., Cortese, R., 1987. Structure and expression of the genes coding for human alpha 1-acid glycoprotein. *EMBO J.* 6 (8), 2289–2296.
- Dockal, M., Carter, D.C., Ruker, F., 1999. The three recombinant domains of human serum albumin: structural characterization and ligand binding properties. *J. Biol. Chem.* 274 (41), 29303–29310.
- Eap, C.B., Cuendet, C., Baumann, P., 1988. Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein. *Naunyn Schmiedeberg's Arch Pharmacol* 337 (2), 220–224.
- Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., Ascenzi, P., 2012. Human serum albumin: from bench to bedside. *Mol. Asp. Med.* 33 (3), 209–290.
- Fasano, M., Curry, S., Terreno, E., Galliano, M., Fanali, G., Narciso, P., Ascenzi, P., 2005. The extraordinary ligand binding properties of human serum albumin. *IUBMB Life* 57 (12), 787–796.
- Fehske, K.J., Schlafer, U., Wollert, U., Müller, W.E., 1982. Characterization of an important drug binding area on human serum albumin including the high-affinity binding sites of warfarin and azapropazone. *Mol. Pharmacol.* 21 (2), 387–393.
- Fernandes, C.L., Ligabue-Braun, R., Verli, H., 2015. Structural glycobiochemistry of human alpha-1-acid glycoprotein and its implications for pharmacokinetics and inflammation. *Glycobiology* 25 (10), 1125–1133.
- Fischer, K., Kettunen, J., Wurtz, P., Haller, T., Havulinna, A.S., Kangas, A.J., Metspalu, A., 2014. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. *PLoS Med.* 11 (2), e1001606.
- Fitos, I., Visy, J., Simonyi, M., Mady, G., Zsila, F., 2010. Selective binding interactions of dermascicane to the genetic variants of human alpha(1)-acid glycoprotein. *Biochim. Biophys. Acta* 1800 (3), 367–372.
- Fitzpatrick, F.A., Wynalda, M.A., 1983. Albumin-catalyzed metabolism of prostaglandin D₂. Identification of products formed in vitro. *J. Biol. Chem.* 258 (19), 11713–11718.
- Fournier, T., Medjoubi-N, N., Porquet, D., 2000. Alpha-1-acid glycoprotein. *Biochim. Biophys. Acta Protein Struct. Mol. Enzymol.* 1482 (1-2), 157–171.
- Fries, E., Gustafsson, L., Peterson, P.A., 1984. Four secretory proteins synthesized by hepatocytes are transported from endoplasmic reticulum to Golgi complex at different rates. *EMBO J.* 3 (1).
- Ghuman, J., Zunszain, P.A., Petitpas, I., Bhattacharya, A.A., Otagiri, M., Curry, S., 2005. Structural basis of the drug-binding specificity of human serum albumin. *J. Mol. Biol.* 353 (1), 38–52.
- Goebel, N.A., Babbey, C.M., Datta-Mannan, A., Witcher, D.R., Wroblewski, V.J., Dunn, K.W., 2008. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. *Mol. Biol. Cell* 19 (12), 5490–5505.
- Gornik, O., Wagner, J., Pucic, M., Knezevic, A., Redzic, I., Lauc, G., 2009. Stability of N-glycan profiles in human plasma. *Glycobiology* 19 (12), 1547–1553.
- Gross, V., Heinrich, P.C., Berg, D., Steube, K., Tran-Thi, T.A., Decker, K., Gerok, W., 1989. Circulatory life time and organ distribution of differently glycosylated forms (unglycosylated, high-mannose type, hybrid type, complex type) of rat alpha-1-acid glycoprotein. In: Baumann, P., Eap, C.B., Müller, W., Tillement, J.P. (Eds.), *Alpha-1-acid Glycoprotein: Genetics, Biochemistry, Physiological Functions, and Pharmacology*, 300. Alan R. Liss, Inc, New York: USA, pp. 231–234.
- Hanada, K., 2017. Lipophilicity influences drug binding to alpha-1-acid glycoprotein F1/S variants but not to the A variant. *Drugs R D* 17 (3), 475–480.
- He, X.M., Carter, D.C., 1992. Atomic structure and chemistry of human serum albumin. *Nature* 358 (6383), 209–215.
- Hein, N.L., Kragh-Hansen, U., Morth, J.P., Jeppesen, M.D., Otzen, D., Møller, J.V., Nissen, P., 2010. Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin. *J. Struct. Biol.* 171 (3), 353–360.
- Hervé, F., Caron, G., Duché, J.-C., Gaillard, P., Abd Rahman, N., Tsantili-Kakoulidou, A., Testa, B., 1998. Ligand specificity of the genetic variants of human α 1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant, 54 (1), 129–138.
- Herve, F., Gomas, E., Duche, J.C., Tillement, J.P., 1993. Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein. *Br. J. Clin. Pharmacol.* 36 (3), 241–249.
- Hocheple, T., Berger, F.G., Baumann, H., Libert, C., 2003. α 1-Acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. *Cytokine Growth Factor Rev.* 14 (1), 25–34.
- Hou, H.N., Qi, Z.D., Ouyang, Y.W., Liao, F.L., Zhang, Y., Liu, Y., 2008. Studies on interaction between Vitamin B12 and human serum albumin. *J. Pharm. Biomed. Anal.* 47 (1), 134–139.
- Hu, M.-L., 1994. [41] Measurement of protein thiol groups and glutathione in plasma, 233, 380–385.
- Huang, Ung, T., 2013. Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics. *Curr. Drug Metabol.* 14 (2), 226–238.
- Israili, Z.H., Dayton, P.G., 2001. Human alpha-1-glycoprotein and its interactions with drugs. *Drug Metab. Rev.* 33 (2), 161–235.
- Jackson, P.R., Tucker, G.T., Woods, H.F., 1982. Altered plasma drug binding in cancer: role of α 1-acid glycoprotein and albumin. *Clin. Pharmacol. Ther.* 32 (3), 295–302.
- Kerns, E.H., Di, L., 2008. Barriers to Drug Exposure in Living Systems Drug-like Properties: Concepts, Structure Design and Methods. Elsevier's Science & Technology, USA, pp. 38–54.
- Kmieć, Z., 2001. Cooperation of Liver Cells in the Regulation of Sinusoidal Contractility Cooperation of Liver Cells In Health and Disease: with 18 Tables. Springer Science & Business Media, Germany, p. 94.
- Kopecký, V., Ettrich, R., Hofbauerová, K., Baumruk, V., 2003. Structure of human α 1-acid glycoprotein and its high-affinity binding site. *Biochem. Biophys. Res. Commun.* 300 (1), 41–46.
- Kragh-Hansen, U., 2016. *Albumin.org*. Retrieved 03/04/2017, from: <http://albumin.org/>.
- Kragh-Hansen, U., Chuang, V.T., Otagiri, M., 2002. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. *Biol. Pharm. Bull.* 25 (6), 695–704.
- Kremer, J.M., Wilting, J., Janssen, L.H., 1988. Drug binding to human alpha-1-acid glycoprotein in health and disease. *Pharmacol. Rev.* 40 (1), 1–47.
- Kurtzals, P., Havelund, S., Jonassen, I., Markussen, J., 1997. Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. *J. Pharm. Sci.* 86 (12), 1365–1368.
- Kushner, I., 1982. The phenomenon of the acute phase response. *Ann. N. Y. Acad. Sci.* 389, 39–48 (1 C-Reacting Pr).
- Lehman-McKeeman, 2013. Absorption, distribution, and excretion of toxicants. In: Klaassen, C. (Ed.), *Casarett and Doull's Toxicology : the Basic Science of Poisons*, eighth ed. ed. McGraw-Hill Education, New York: United States, pp. 151–180. c2013.
- Lentner, C., 1984. Geigy scientific tables. In: Lentner, C. (Ed.), *Physical Chemistry, Composition of Blood, Hematology, Somatometric data*. (8th Review and Engl. ed., Vol. 3 CIBA-GEIGY, West Caldwell, NJ, pp. 135–137, 140–142.
- Li, Y., Yan, X.P., Chen, C., Xia, Y.L., Jiang, Y., 2007. Human serum albumin-mercurial species interactions. *J. Proteome Res.* 6 (6), 2277–2286.
- Maciazek-Jurczyk, M., Szkudlarek, A., Chudzik, M., Pozycka, J., Sulkowska, A., 2018. Alteration of human serum albumin binding properties induced by modifications: a review. *Spectrochim. Acta A Mol. Biomol. Spectrosc.* 188, 675–683.
- Majorek, K.A., Porebski, P.J., Dayal, A., Zimmerman, M.D., Jablonska, K., Stewart, A.J., Minor, W., 2012. Structural and immunologic characterization of bovine, horse, and rabbit serum albumins. *Mol. Immunol.* 52 (3-4), 174–182.
- Markus, G., Karush, F., 1957. The disulfide bonds of human serum albumin and bovine γ -globulin. *J. Am. Chem. Soc.* 79 (1), 134–139.
- Maruyama, T., Otagiri, M., Takadate, A., 1990. Characterization of drug binding sites on alpha 1-acid glycoprotein. *Chem. Pharm. Bull. (Tokyo)* 38 (6), 1688–1691.
- Meijer, D.K.F., Nijssen, 1991. Transport of drugs, proteins and drug-protein conjugates. In: Ballet, F., Thurman, R.G. (Eds.), *Research in Perfused Liver*. John Libbey & Company Ltd, England, France and Italy, pp. 165–208.
- Meijer, D.K.F., van der Sluis, P., 1989. Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery. *Pharm. Res.* 6 (2), 105–118.
- Meloun, B., Morávek, L., Kostka, V., 1975. Complete amino acid sequence of human serum albumin. *FEBS (Fed. Eur. Biochem. Soc.) Lett.* 58 (1-2), 134–137.
- Miller, L.L., 1951. The dominant role of the liver in plasma protein synthesis: a direct study of the isolated perfused rat liver with the aid of lysine- ϵ -C14. *J. Exp. Med.* 94 (5), 431–453.
- Minghetti, P., Ruffner, D., Kuang, W., Dennison, O., Hawkins, J., Beattie, W., Dugaiczky, A., 1986. Molecular structure of the human albumin gene is revealed by nucleotide sequence within 911-22 of chromosome 4. *J. Biol. Chem.* 261 (15), 6747–6757.
- Montiel, M.D., Carracedo, A., Blazquez-Caeiro, J.L., Andrade-Vide, C., 1990. Orosomucoid (ORM1 and ORM2) types in the Spanish Basque country, galicia and northern Portugal. *Hum. Hered.* 40 (6), 330–334.
- Müller, W.E., 1989. Drug binding sites on human alpha-1-acid glycoprotein. *Prog. Clin. Biol. Res.* 300, 363–378.
- Nishi, K., Komine, Y., Fukunaga, N., Maruyama, T., Suenaga, A., Otagiri, M., 2006. Involvement of disulfide bonds and histidine 172 in a unique beta-sheet to alpha-helix transition of alpha 1-acid glycoprotein at the biomembrane interface. *Proteins* 63 (3), 611–620.
- Nurdiansyah, R., Rifa'i, M., Widodo, 2016. A comparative analysis of serum albumin from different species to determine a natural source of albumin that might be useful for human therapy. *J. Taibah University Med. Sci.* 11 (3), 243–249.
- Oettl, K., Stauber, R.E., 2007. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. *Br. J. Pharmacol.* 151 (5), 580–590.

- Otagiri, M., Chuang, V.T.G., 2016. In: Otagiri, M., Chuang, V.T.G. (Eds.), *Albumin in Medicine Pathological and Clinical Applications*. Springer Nature, Singapore.
- Peters Jr., T., 1996. In: Peters, T. (Ed.), *All about Albumin: Biochemistry, Genetics, and Medical Applications*, United States of America. Academic Press.
- Peters, T., Anfinsen, C.B., 1950. Net production OF serum albumin BY liver slices. *J. Biol. Chem.* 186 (2), 805–813.
- Pettifer, G., 2003. Fluids, electrolytes, and acid-base therapy. In: Slatter, D.H. (Ed.), *Textbook of Small Animal Surgery*, third ed., volume 1, pp. 17–43.
- Piafsky, K.M., 1980. Disease-induced changes in the plasma binding of basic drugs. *Clin. Pharmacokinet.* 5 (3), 246–262.
- Piafsky, K.M., Borga, O., 1977. Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation. *Clin. Pharmacol. Ther.* 22 (5 Pt 1), 545–549.
- Putnam, F.W., 1984. Alpha, Beta, Gamma, omega – the Structure of the Plasma Proteins *The Plasma Proteins: Structure, Function, and Genetic Control*, second ed., 4. Academic Press, Orlando, pp. 45–166.
- Quiming, N.S., Vergel, R.B., Nicolas, M.G., Villanueva, J.A., 2005. Interaction of bovine serum albumin and metallothionein. *J. Health Sci.* 51 (1), 8–15.
- Quinlan, G.J., Martin, G.S., Evans, T.W., 2005. Albumin: biochemical properties and therapeutic potential. *Hepatology* 41 (6), 1211–1219.
- Roda, A., Cappelleri, G., Aldini, R., Roda, E., Barbara, L., 1982. Quantitative aspects of the interaction of bile acids with human serum albumin. *JLR (J. Lipid Res.)* 23 (3), 490–495.
- Rothschild, M.A., Oratz, M., Schreiber, S.S., 1988. Serum albumin. *Hepatology* 8 (2), 385–401.
- Routledge, 1989. Clinical relevance of alpha 1 acid glycoprotein in health and disease. In: Baumann, P., Eap, B.C., Muller, W., Tillement, J.P. (Eds.), *Alpha-1-acid Glycoprotein: Genetics, Biochemistry, Physiological Functions and Pharmacology*, 300. Alan R. Liss, New York: USA, pp. 185–198.
- Sadler, P.J., Viles, J.H., 1996. ¹H and ¹¹³Cd NMR investigations of Cd²⁺ and Zn²⁺ Binding sites on serum albumin: competition with Ca²⁺, Ni²⁺, Cu²⁺, and Zn²⁺. *Inorg. Chem.* 35 (15), 4490–4496.
- Sand, K.M., Bern, M., Nilsen, J., Noordzij, H.T., Sandlie, I., Andersen, J.T., 2014. Unraveling the interaction between FeRn and albumin: opportunities for design of albumin-based therapeutics. *Front. Immunol.* 5, 682.
- Sarcione, E.J., 1963. Synthesis of α1-acid glycoprotein by the isolated perfused rat liver. *Arch. Biochem. Biophys.* 100 (3), 516–519.
- Schmid, 1950. Preparation and properties of an acid glycoprotein prepared from human plasma. *J. Am. Chem. Soc.* 72 (6), 2816–2816.
- Schmid, 1989. Human plasma alpha1-acid glycoprotein-Biochemical properties, the amino acid sequence and the structure of the carbohydrate moiety, variants and polymorphism. In: Baumann, P., Eap, B.C., Walter, M., Tillement, J.P. (Eds.), *Alpha1-acid Glycoprotein*, 300. Alan R Liss, New York: USA, pp. 7–22.
- Schmid, Kaufmann, H., Isemura, S., Bauer, F., Emura, J., Motoyama, T., Nanno, S., 1973. Structure of α1-acid glycoprotein. The complete amino acid sequence, multiple amino acid substitutions, and homology with immunoglobulins. *Biochemistry* 12, 2711–2724.
- Schmid, K., Nimerg, R.B., Kimura, A., Yamaguchi, H., Binette, J.P., 1977. The carbohydrate units of human plasma α1-acid glycoprotein. *Biochim. Biophys. Acta* 492, 291–302.
- Schonfeld, D.L., Ravelli, R.B., Mueller, U., Skerra, A., 2008. The 1.8-Å crystal structure of alpha1-acid glycoprotein (Orosomucoid) solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin. *J. Mol. Biol.* 384 (2), 393–405.
- Singh-Manoux, A., Shipley, M.J., Bell, J.A., Canonico, M., Elbaz, A., Kivimaki, M., 2017. Association between inflammatory biomarkers and all-cause, cardiovascular and cancer-related mortality. *CMAJ (Can. Med. Assoc. J.)* 189 (10), E384–E390.
- Stamler, J.S., Jaraki, O., Osborne, J., Simon, D.I., Keaney, J., Vita, J., Loscalzo, J., 1992. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. *Proc. Natl. Acad. Sci.* 89 (16), 7674–7677.
- Sudlow, G., Birkett, D.J., Wade, D.N., 1975. The characterization of two specific drug binding sites on human serum albumin. *Mol. Pharmacol.* 11 (6), 824–832.
- Sudlow, G., Birkett, D.J., Wade, D.N., 1976. Further characterization of specific drug binding sites on human serum albumin. *Mol. Pharmacol.* 12, 1052–1061.
- Taguchi, K., Nishi, K., Giam Chuang, V.T., Maruyama, T., Otagiri, M., 2013. Molecular aspects of human alpha-1 acid glycoprotein — structure and function. InTech.
- Tayeh, N., Rungassamy, T., Albani, J.R., 2009. Fluorescence spectral resolution of tryptophan residues in bovine and human serum albumins. *J. Pharm. Biomed. Anal.* 50 (2), 107–116.
- Turell, L., Radi, R., Alvarez, B., 2013. The thiol pool in human plasma: the central contribution of albumin to redox processes. *Free Radic. Biol. Med.* 65, 244–253.
- van Dijk, W., Pos, O., van der Stelt, M., Moshage, H., Yap, S., Dente, L., Eap, C., 1991. Inflammation-induced changes in expression and glycosylation of genetic variants of α1-acid glycoprotein. *Biochem. J.* 1 (276), 343–347.
- Walsh, C.T., Garneau-Tsodikova, S., Gatto Jr., G.J., 2005. Protein posttranslational modifications: the chemistry of proteome diversifications. *Angew Chem. Int. Ed. Engl.* 44 (45), 7342–7372.
- Wanat, K., Brzezinska, E., Sobanska, A.W., 2018. Aspects of drug-protein binding and methods of analyzing the phenomenon. *Curr. Pharmaceut. Des.* 24 (25), 2974–2985.
- Wang, Peterson, S.E., Loring, J.F., 2014. Protein post-translational modifications and regulation of pluripotency in human stem cells. *Cell Res.* 24 (2), 143–160.
- Weber, G., 1975. Energetics of ligand binding to proteins, 29, 1–83.
- Weimer, H.E., Mehl, J.W., Winzler, R.J., 1950. Studies on the mucoproteins of human plasma V. Isolation and characterization of a homogeneous mucoprotein. *J. Biol. Chem.* 185 (2), 561–568.
- Wu, D., Struwe, W.B., Harvey, D.J., Ferguson, M.A.J., Robinson, C.V., 2018. N-glycan microheterogeneity regulates interactions of plasma proteins. *Proc. Natl. Acad. Sci. U. S. A.*
- Yang, Petersen, C.E., Ha, C.E., Bhagavan, N.V., 2002. Structural insights into human serum albumin-mediated prostaglandin catalysis. *Protein Sci.* 11 (3), 538–545.
- Yang, F., Zhang, Y., Liang, H., 2014. Interactive association of drugs binding to human serum albumin. *Int. J. Mol. Sci.* 15 (3), 3580–3595.
- Yeggoni, D.P., Manidhar, D.M., Suresh Reddy, C., Subramanyam, R., 2016. Investigation of binding mechanism of novel 8-substituted coumarin derivatives with human serum albumin and alpha-1-glycoprotein. *J. Biomol. Struct. Dyn.* 34 (9), 2023–2036.
- Yeggoni, D.P., Rachamalla, A., Subramanyam, R., 2016. A comparative binding mechanism between human serum albumin and α-1-acid glycoprotein with corilagin: biophysical and computational approach. *RSC Adv.* 6 (46), 40225–40237.
- Yoshima, H., Matsumoto, A., Mizuochi, T., Kawasaki, T., Kob, A., 1981. Comparative study of the carbohydrate moieties of rat and human plasma α1-acid glycoproteins. *J. Biol. Chem.* 256 (16), 8476–8484.
- Yuasa, I., Umetsu, K., Vogt, U., Nakamura, H., Nanba, E., Tamaki, N., Irizawa, Y., 1997. Human orosomucoid polymorphism: molecular basis of the three common ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S. *Hum. Genet.* 99 (3), 393–398.
- Zsila, F., 2013. Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model. *Mol. Pharm.* 10 (5), 1668–1682.